Review Article
N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence
Table 2
Summary of included reviews: N-acetylcysteine for schizophrenia.
| Authors (Year) | Type | Inclusion | No. Studies (Study Size) | Conclusion |
| Chen et al (2016) [26] | SR | Double-blind RCTs of NAC in schizophrenia. | Total = 2 (n = 186) | Adjunctive NAC may be effective in reducing negative and general symptoms in schizophrenia. |
| Zheng et al (2018) [27] | SR+MA | All published randomised RCTs of NAC for major mental disorders with meta-analysable data. | Total = 3 (n = 307) | N-acetylcysteine significantly improved total psychopathology in schizophrenia (SMD = -0.74, 95% CI: -1.43, -0.06; I2 = 84%, P = 0.03). |
|
|
Abbreviation. Confidence interval (CI); meta-analysis (MA); N-acetylcysteine (NAC); randomised control trial (RCT); standard mean difference (SMD); systematic review (SR).
|